Evaluation of a fibroelastoma with magnetic resonance imaging.

Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205–2209. 8. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzymeA reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723–1730. 9. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291–1295. 10. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progresión of aortic stenosis. J Am Coll Cardiol 2007;49:554–561. 11. Rossebø AB, Pedersen TR, Allen C et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970–973. 12. Jassal DS, Tam JW, Bhagirath KM, Gaboury I, Sochowski RA, Dumesnil JG, Giannoccaro PJ, Jue J, Pandey AS, Joyner CD, Teo KK, Chan KL. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progresion observation measuring effects of rosuvastatin (ASTRONOMER) study. Eur Heart J 2008;29:1542–1547. First published on April 28, 2008. doi:10.1093/eurheartj/ehn172. 13. Fulkerson PK, Beaver BM, Auseon JC, Graber HL. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med 1979;66:967–977. 14. Davies MJ, Treasure T, Parker DJ. Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Heart 1996;75:174–178.